Tim Lohoff PhD
Principal
Slate Medicines is a biotech company focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.
The company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders.
Industry
Biotech
Year Invested
2026
Status
Current
Location
Raleigh, North Carolina
$130M
Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders
Forbion team
Rogier Rooswinkel PhD
General Partner
Vincent Loon MSc
Business Analyst
Luuk de Vries PhD
Analyst
Nat Kolber PhD
Fellow